anti-cdh17 car-t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 8, 2024 (NCT06501183)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cadherin-17Immunity, active
CDH17 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06820424 | Early Phase 1 (Phase 1) | Mar 31, 2025 | Guangzhou Bio-gene Technology Co., Ltd., People's Liberation Army of China |
| NCT06937567 | Early Phase 1 (Phase 1) | Dec 26, 2024 | UTC Therapeutics Inc., Zhejiang University |
| NCT06501183 | Phase 1 | Jul 8, 2024 | Ningxia Medical University, UTC Therapeutics Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UTC Therapeutics Inc. | For profit | 2 | 0 | 1 | 2024 |
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 1 | 0 | 1 | 2025 |
| Ningxia Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1